PP
TARS icon

PDT Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

PDT Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.42M Hold
63,026
– – 0.26% 123
2025
Q4 		$5.16M Hold
63,026
– – 0.33% 94
2025
Q3 		$3.75M Hold
63,026
– – 0.24% 152
2025
Q2 		$2.55M Buy
+63,026
New +$2.84M 0.14% 246

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PDT Partners's TARS Position: Q1 2026 in Review

PDT Partners held its Tarsus Pharmaceuticals (TARS) position steady in Q1 2026 at 63,026 shares worth $4.42M. The position accounts for 0.26% of the portfolio, ranked #123.

PDT Partners first reported a position in TARS in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.16M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • PDT Partners held 63,026 shares of Tarsus Pharmaceuticals worth $4.42M as of Q1 2026.
  • PDT Partners left its Tarsus Pharmaceuticals share count unchanged in Q1 2026.
  • Tarsus Pharmaceuticals made up 0.26% of PDT Partners's portfolio in Q1 2026, its #123 holding.
  • PDT Partners first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • PDT Partners's Tarsus Pharmaceuticals position peaked at $5.16M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.